Avtal | $24,000,000 | (Mar 20, 2026)
games2gether | $5,202,945 | (Mar 20, 2026)
Claros | $30,000,000 | (Mar 20, 2026)
Certified by Founder
Lodge
Carmot Therapeutics, Inc.
start up
United States
- Berkeley
- 26/07/2022
- Series D
- $160,000,000
Carmot Therapeutics, Inc. is a clinical-stage company dedicated to the discovery and development of innovative medicines. Carmot applies a transformative, patented drug discovery approach, Chemotype Evolution to explore novel frontiers of chemistry and biology. Using Chemotype Evolution, Carmot has developed a portfolio of drug candidates in metabolic disease and oncology.
- Industry Biotechnology Research
- Website https://carmot-therapeutics.us/contact-us/
- LinkedIn https://www.linkedin.com/company/carmot-therapeutics-inc/
Latent | $80,000,000 | (Mar 20, 2026)
Corridor | $25,000,000 | (Mar 20, 2026)
RunSybil | $40,000,000 | (Mar 20, 2026)
Ezra AI Labs | $3,200,000 | (Mar 20, 2026)
Parallel(FRANCE) | $20,000,000 | (Mar 20, 2026)
Health Universe | $6,000,000 | (Mar 20, 2026)
PADO AI | $6,000,000 | (Mar 20, 2026)
Edra | $30,000,000 | (Mar 20, 2026)
Chalkie AI | $4,000,000 | (Mar 20, 2026)
Deeptune | $43,000,000 | (Mar 20, 2026)